Protocol Ledger

NCT05063552 · Phase II/III · ACTIVE NOT RECRUITING

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Interventional Phase II/III clinical trial protocol NCT05063552 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-13 Enrollment: 430 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05063552
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)430 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05063552
Protocol FieldVerified Registry Value
NCT IdentifierNCT05063552
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment430 participants (ESTIMATED)
Registered Start Date2023-03-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI